II
DNTH icon

Ishara Investments’s Dianthus Therapeutics DNTH Stock Holding History

Ishara Investments’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,000
Closed -$989K – 48
2025
Q4 		$989K Buy
+24,000
New +$930K 1.13% 32

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Ishara Investments's DNTH Position: Q1 2026 in Review

Ishara Investments sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 24,000 shares — an estimated $989K sold.

Ishara Investments first reported a position in DNTH in Q4 2025 and held it in 1 quarter. The position peaked at $989K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Ishara Investments reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ishara Investments sold 24,000 Dianthus Therapeutics shares in Q1 2026, an estimated $989K.
  • Ishara Investments first reported a position in Dianthus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Ishara Investments's Dianthus Therapeutics position peaked at $989K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Ishara Investments's 13F filing for Q1 2026, filed 15 May 2026.